Rare but Serious Risks Associated with Ketamine
Rare but Serious Risks Associated with Ketamine
While most patients receiving ketamine or esketamine under proper medical supervision experience only the common, short-lived side effects described in a companion article elsewhere in this series, there are additional risks that, while less frequent, are more serious and warrant clear, direct discussion. Understanding these risks — and the role that proper screening and monitoring play in managing them — is an essential part of making an informed decision about treatment.
Significant Blood Pressure Elevation
While mild to moderate increases in blood pressure are a common and expected effect of ketamine, discussed in the companion article on common side effects, a smaller subset of patients can experience more significant blood pressure elevation during treatment. This is a particular concern for patients with pre-existing, poorly controlled hypertension, certain cardiovascular conditions, or a history of aneurysm, which is why thorough cardiovascular screening before starting treatment — and continuous blood pressure monitoring during each session — is a standard and important safety practice at reputable clinics, and why patients with significant uncontrolled cardiovascular disease may not be appropriate candidates for treatment, a topic explored further in the article on patient eligibility elsewhere in this series.
Respiratory Depression
Although ketamine is generally noted for its relatively preserved respiratory drive compared to many other anesthetic agents — one of its original advantages, discussed in the article on its historical development — respiratory depression (dangerously slowed or shallow breathing) remains a recognized risk, particularly at higher doses, when combined with other sedating substances, or in patients with certain underlying respiratory conditions. This is one of several reasons ketamine should only be administered in a setting equipped to monitor oxygen levels and respond to any breathing-related complications.
Severe or Persistent Psychological Reactions
While the dissociative experience associated with ketamine treatment is expected and generally resolves within a couple of hours, a smaller number of patients experience more intense psychological reactions, sometimes described as frightening or distressing rather than simply unusual. In rare cases, this can include significant anxiety, panic, or paranoid thinking during the session. Reputable providers screen for risk factors that may increase this likelihood — including a personal or strong family history of psychosis — and monitor patients closely throughout treatment so that support can be provided promptly if a difficult psychological reaction occurs.
Risk in Patients With a History of Psychosis
Ketamine and related NMDA receptor antagonists have been studied, including in research settings, for their ability to transiently model certain symptoms of psychosis in healthy volunteers, which reflects a genuine pharmacological interaction with brain systems implicated in psychotic disorders. Because of this, patients with a personal history of psychotic disorders, such as schizophrenia, are generally considered poor candidates for ketamine treatment, and this is one of the more consistently emphasized screening criteria across reputable ketamine and esketamine treatment protocols, discussed in more detail in the article on patient eligibility elsewhere in this series.
Bladder and Urinary Tract Damage (Ketamine Cystitis)
One of the most serious risks associated with ketamine is a condition known as ketamine-induced cystitis, or ketamine bladder syndrome, involving inflammation and, with continued exposure, potentially permanent damage to the bladder wall. This condition is discussed in detail in a dedicated article later in this series, but it’s important to note here that it has been documented overwhelmingly in the context of frequent, heavy, typically recreational ketamine use over extended periods, rather than in patients receiving occasional, medically supervised, appropriately dosed treatment sessions. Nonetheless, it is a serious enough risk that any ketamine treatment program should include some monitoring for urinary symptoms, particularly for patients receiving treatment over an extended period.
Cognitive Effects With Long-Term or Heavy Use
Some research, again drawn largely from studies of frequent recreational users, has raised questions about potential effects on memory and cognitive function with long-term, heavy ketamine exposure. The relevance of these findings to patients receiving occasional, medically supervised, lower-dose treatment is less clear and is an area of ongoing research, discussed in more detail in a separate article on long-term safety later in this series.
Dependence and Misuse Potential
Ketamine carries a recognized potential for psychological dependence, particularly with frequent or unsupervised use, which is reflected in its classification as a Schedule III controlled substance in the United States and in the boxed warning included in esketamine’s FDA labeling specifically addressing misuse and abuse potential. In supervised medical settings, with appropriate screening for personal or family history of substance use disorders and adherence to appropriately spaced treatment protocols, this risk is actively managed, though it is not eliminated entirely, which is part of why ongoing clinical oversight throughout a course of treatment matters, rather than treatment being a one-time evaluation followed by unsupervised, indefinite use.
Interactions With Other Substances and Medications
Ketamine can interact with other central nervous system depressants, including alcohol, benzodiazepines, and opioid medications, potentially increasing the risk of excessive sedation or respiratory depression. This is why a thorough medication and substance use history is a standard part of pre-treatment screening, and why patients are generally advised against using alcohol or other sedating substances around the time of treatment sessions.
Increased Suicidal Ideation (Rare, Complex Relationship)
It’s worth noting directly that esketamine’s FDA labeling includes information about suicidal thoughts and behaviors, reflecting the complex reality that treatment-resistant depression itself carries an elevated baseline risk of suicidality, and that clinical trial monitoring has tracked this closely. This is precisely why esketamine received a specific additional FDA approval for depressive symptoms with suicidal ideation — a reflection of clinical trial data showing rapid symptom improvement in this specific, high-risk population — but it also underscores why ongoing psychiatric monitoring, not just monitoring during the treatment session itself, remains an essential part of any ketamine or esketamine treatment program.
Why Screening and Monitoring Matter So Much
Nearly every risk described in this article is one that appropriate patient screening and ongoing clinical monitoring can help identify and manage. This is why a legitimate, reputable ketamine or esketamine treatment program invests significant effort in a thorough pre-treatment evaluation — covering medical history, psychiatric history, current medications, substance use history, and cardiovascular risk factors — rather than treating ketamine as a low-oversight, walk-in procedure. It’s also why ongoing monitoring throughout a course of treatment, not just an initial evaluation, is considered a core standard of care rather than an optional extra.
What Patients Should Ask About Serious Risks
Patients considering ketamine or esketamine treatment may want to directly ask a prospective provider:
– What screening process is used to identify patients who may be at higher risk for serious complications?
– What emergency protocols and equipment are in place at this facility in case of a serious adverse reaction?
– How will my urinary and bladder health be monitored if I’m receiving treatment over an extended period?
– What is the plan for ongoing psychiatric monitoring throughout my course of treatment, not just during individual sessions?
The Bottom Line
While ketamine’s common side effects are generally mild and short-lived, a smaller set of more serious risks — including significant blood pressure changes, respiratory depression, severe psychological reactions, bladder damage with prolonged heavy use, and dependence potential — deserve clear-eyed attention. These risks are precisely why thorough screening, ongoing monitoring, and treatment through a qualified, experienced provider are not optional formalities but central components of using ketamine safely and responsibly in a medical context.
*This article is for educational purposes only and does not constitute medical advice. Anyone considering ketamine or esketamine treatment should discuss their full medical and psychiatric history with a licensed healthcare provider to assess individual risk factors.*